Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18672796 | Targeting Nrip1 to Alleviate Metabolic Disease | May 2024 | May 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18671080 | METHODS AND COMPOSITIONS FOR INSERTION OF ANTIBODY CODING SEQUENCES INTO A SAFE HARBOR LOCUS | May 2024 | February 2026 | Abandon | 21 | 1 | 1 | No | No |
| 18663564 | MICRO-ENGINEERED MODELS OF THE HUMAN EYE AND METHODS OF USE | May 2024 | August 2025 | Allow | 15 | 0 | 1 | Yes | No |
| 18616811 | GENE EXPRESSION SYSTEM FOR PROBIOTIC MICROORGANISMS | March 2024 | September 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18424664 | METHOD FOR GENERATING T CELL LINEAGE POPULATIONS FROM STEM/PROGENITOR CELLS | January 2024 | February 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18411991 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | January 2024 | February 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18410900 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | January 2024 | October 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18178849 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17928414 | ENGINEERED IMMUNE CELLS, COMPOSITIONS AND METHODS THEREOF | November 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17760378 | METHODS OF INCREASING MATURATION OF HEART, PANCREATIC BETA-CELLS, AND NEURONS | August 2022 | September 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17785946 | METHODS OF CULTURING T CELLS WITH A 4-1BBL FUSION POLYPEPTIDE AND USES OF SAME | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17748997 | IMMUNOTHERAPIES FOR TARGETING OF TUMOR VASCULATURE | May 2022 | March 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17744266 | ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS | May 2022 | April 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17662629 | TARGETING WNT SIGNALING FOR IMPROVED GLIOMA IMMUNOTHERAPY | May 2022 | November 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17755750 | ENGINEERED T CELL RECEPTORS AND USES THEREOF | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17659432 | SYSTEM, DEVICE, AND METHOD FOR CELL CRYOPRESERVATION VIA SAND-MEDIATED ICE SEEDING | April 2022 | May 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17311466 | TUMOR COMBINED IMMUNOTHERAPY | March 2022 | November 2025 | Abandon | 53 | 0 | 1 | No | No |
| 17642622 | NK CELL IMMUNOTHERAPY COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING SAME | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17680379 | HUMANIZED MOUSE MODELS OF THE FCRN RECYCLING PATHWAY | February 2022 | July 2024 | Allow | 29 | 1 | 1 | No | No |
| 17575787 | Platform Oncolytic Vector for Systemic Delivery | January 2022 | July 2025 | Allow | 42 | 4 | 1 | Yes | No |
| 17646398 | METHOD FOR CULTURING CELLS INTO WHICH REPROGRAMMING FACTOR IS INTRODUCED | December 2021 | October 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17553391 | PROSTATE CANCER CHIMERIC ANTIGEN RECEPTORS | December 2021 | March 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17541917 | MULTICISTRONIC MIRNA DELIVERY FOR CARDIAC REPROGRAMMING | December 2021 | March 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17530855 | METHOD OF PRODUCING PLACENTA-LIKE ORGANOID, PLACENTA-LIKE ORGANOID, AND PRODUCTION OR TEST KIT | November 2021 | October 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17605510 | HIGH DENSITY LIPOPROTEIN NANOPARTICLES AND RNA TEMPLATED LIPOPROTEIN PARTICLES FOR OCULAR THERAPY | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17504317 | Mercury Controlled Gene Expression | October 2021 | November 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17498158 | Platform Oncolytic Vector for Systemic Delivery | October 2021 | April 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17497367 | Targeting Nrip1 to Alleviate Metabolic Disease | October 2021 | February 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17601384 | MODIFIED IMMUNE RECEPTOR CONSTRUCTS | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17441674 | MODIFIED IMMUNE EFFECTOR CELLS WITH INCREASED RESISTANCE TO CELL DEATH | September 2021 | July 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17480473 | ENGINEERED IMMUNE CELLS WITH DOMINANT SIGNALS | September 2021 | September 2024 | Allow | 36 | 3 | 0 | Yes | No |
| 17474535 | RECOMBINANT ADENO ASSOCIATED VIRUS ENCODING CLARIN-1 AND USES THEREOF | September 2021 | June 2024 | Allow | 33 | 3 | 0 | Yes | No |
| 17438380 | HIGH AVIDITY WT1 T CELL RECEPTORS AND USES THEREOF | September 2021 | June 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17436306 | COMPOSITION, CULTURE MEDIUM AND METHOD FOR INDUCING AND/OR AMPLIFYING TSCM IN VITRO | September 2021 | February 2026 | Abandon | 54 | 2 | 1 | No | No |
| 17380214 | CELL CULTURE SCAFFOLD MATERIAL, RESIN FILM, CELL CULTURE VESSEL, AND METHOD FOR CULTURING A CELL | July 2021 | February 2025 | Abandon | 43 | 3 | 1 | Yes | No |
| 17377830 | LENTIVIRUS PACKAGING SYSTEM, LENTIVIRUS PRODUCED BY THE SAME, CELL TRANSDUCED BY THE LENTIVIRUS, METHOD FOR IMPROVING LENTIVIRUS PRODUCTION IN A HOST CELL, AND METHOD OF USING THE CELL FOR TREATING CANCER | July 2021 | March 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17374157 | MICROCARRIERS WITH SCAFFOLD STRUCTURE AND CONTINUOUS OUTER WALL FOR CULTURING CELLS | July 2021 | March 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17304687 | DEVICE FOR CELL CULTURE AND CELL CULTURING METHOD | June 2021 | November 2025 | Abandon | 52 | 6 | 1 | Yes | No |
| 17415239 | A PHYSIOLOGICAL BIOMIMETIC CULTURE SYSTEM FOR HEART SLICES | June 2021 | August 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17326661 | Novel T-Cell Receptor and Ligand | May 2021 | May 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17290708 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | April 2021 | June 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17236726 | METHODS AND MATERIALS FOR TREATING OSTEOARTHRITIS | April 2021 | December 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17224909 | Treatment of Acute Respiratory Distress Syndrome by T Regulatory Cells | April 2021 | February 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17270943 | THERAPEUTIC AGENTS COMPRISING NUCLEIC ACIDS AND TCR MODIFIED IMMUNE CELLS AND USES THEREOF | February 2021 | September 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 17264485 | METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLS | January 2021 | December 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17152136 | CANCER TARGETS AND USES THEREOF | January 2021 | March 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17248071 | LIVESTOCK ANIMALS WITH IMPROVED GROWTH PERFORMANCE | January 2021 | June 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17251272 | IMMUNODEFICIENT MOUSE | December 2020 | March 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17057945 | METHODS FOR ISOLATING TUMOR-SPECIFIC IMMUNE CELLS FROM A SUBJECT FOR ADOPTIVE CELL THERAPY AND CANCER VACCINES | November 2020 | February 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17056157 | SCAFFOLDS WITH STABILIZED MHC MOLECULES FOR IMMUNE-CELL MANIPULATION | November 2020 | October 2025 | Allow | 59 | 2 | 1 | Yes | No |
| 17088845 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | November 2020 | September 2025 | Allow | 58 | 4 | 0 | Yes | Yes |
| 17051353 | NEURAL STEM CELL COMPOSITIONS INCLUDING CHIMERIC POXVIRUSES FOR CANCER TREATMENT | October 2020 | January 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17050805 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | October 2020 | May 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17080185 | GENE EXPRESSION SYSTEM FOR PROBIOTIC MICROORGANISMS | October 2020 | January 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17050045 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | October 2020 | May 2025 | Allow | 55 | 2 | 1 | Yes | No |
| 17078742 | PERFUSION PLATE FOR MICROARRAY 3D BIOPRINTING | October 2020 | July 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17049956 | IMMATURE DENTAL PULP STEM CELLS AND METHODS OF USE TO TREAT BONE MARROW FAILURE | October 2020 | November 2024 | Abandon | 49 | 1 | 1 | No | No |
| 17074074 | MICRO-ENGINEERED MODELS OF THE HUMAN EYE AND METHODS OF USE | October 2020 | February 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 17070368 | THREE DIMENSIONAL HYDROGEL FOR CULTURING OF CELLS | October 2020 | April 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17046850 | PRODUCTION OF MEGAKARYOCYTES IN BIOREACTORS | October 2020 | August 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 17043173 | CELL PRODUCTION METHOD | September 2020 | July 2025 | Abandon | 58 | 4 | 1 | Yes | No |
| 17028836 | METHODS FOR SCREENING GENETIC PERTURBATIONS | September 2020 | November 2023 | Allow | 37 | 3 | 0 | Yes | No |
| 17025953 | COST EFFECTIVE CULTURE MEDIA AND PROTOCOL FOR HUMAN INDUCED PLURIPOTENT STEM CELLS | September 2020 | May 2025 | Abandon | 56 | 3 | 1 | Yes | No |
| 16980359 | FOAMY VIRUSES AND METHODS OF USE | September 2020 | October 2024 | Allow | 49 | 1 | 1 | Yes | No |
| 17018728 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | September 2020 | April 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 16977346 | TRANSDUCTION AND EXPANSION OF CELLS | September 2020 | August 2025 | Allow | 59 | 4 | 1 | Yes | No |
| 17004080 | OPTIMIZED IN VITRO CELLULAR SYSTEM FOR BBB PERMEABILITY LINKED NEUROACTIVITY SCREENING | August 2020 | May 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16971971 | A CD19-BASED CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF | August 2020 | January 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 16968392 | FREE-STANDING, TRANSFERRABLE VASCULAR NETWORKS VIA GUIDED SELF-ASSEMBLY AND USE IN CELL REPLACEMENT THERAPIES | August 2020 | December 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16988145 | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO INTESTINAL EPITHELIAL CELLS | August 2020 | May 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 16960529 | MIRNA MODULATION OF T CELL SIGNALING AND USES THEREOF | July 2020 | June 2025 | Abandon | 59 | 4 | 1 | No | No |
| 16956230 | DIGITALIZED HUMAN ORGANOIDS AND METHODS OF USING SAME | June 2020 | February 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 16954349 | ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF | June 2020 | April 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 16767931 | SHUTTLE PLASMID REPLICABLE IN CLOSTRIDIUM AND E. COLI AND RECOMBINANT MICROORGANISM PREPARED THEREWITH AND HAVING ENHANCED PENTOSE METABOLISM AND FERMENTATION PERFORMANCE | May 2020 | March 2025 | Abandon | 57 | 2 | 1 | No | No |
| 15930947 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | May 2020 | June 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16759632 | EUKARYOTIC CELL LINE | April 2020 | February 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16838709 | METHODS AND COMPOSITIONS FOR INSERTION OF ANTIBODY CODING SEQUENCES INTO A SAFE HARBOR LOCUS | April 2020 | October 2024 | Abandon | 55 | 4 | 1 | No | No |
| 16649522 | METHODS FOR OBTAINING CARDIOMYOGENIC PRECURSOR CELLS | March 2020 | August 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16811672 | Systems and Methods for Automated Processing of Signals from Cardiomyocytes in an Unbiased Manner | March 2020 | July 2023 | Abandon | 41 | 1 | 0 | Yes | No |
| 16798465 | Therapeutic compositions and applications that comprise nucleic acids and adoptively transferred immune cell | February 2020 | August 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16622800 | EXPRESSION VECTORS COMPRISING ENGINEERED GENES | December 2019 | June 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16607834 | GENE THERAPY FOR OCULAR DISORDERS | October 2019 | August 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16585286 | METHODS FOR INTEGRATION OF TRANSGENE DNA | September 2019 | April 2023 | Abandon | 42 | 0 | 1 | No | No |
| 16528572 | HYALURONIC ACID COATED CHIMERIC VIRAL/NONVIRAL NANOPARTICLES | July 2019 | August 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16458326 | Inhibition of Fibrosis and AF By TGF-Beta Inhibition in the Posterior Left Atrium (PLA) | July 2019 | March 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16466265 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | June 2019 | November 2023 | Allow | 53 | 4 | 1 | Yes | No |
| 15527685 | TKI PERMEABILITY ENHANCERS | May 2017 | May 2023 | Allow | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZHU, JIANJIAN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ZHU, JIANJIAN works in Art Unit 1631 and has examined 68 patent applications in our dataset. With an allowance rate of 54.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner ZHU, JIANJIAN's allowance rate of 54.4% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZHU, JIANJIAN receive 1.99 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ZHU, JIANJIAN is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +88.1% benefit to allowance rate for applications examined by ZHU, JIANJIAN. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.6% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 31.8% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.